uromune mv140 emerging drug insight and market forecast

“Uromune (MV140) Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Uromune (MV140) for uncomplicated Urinary Tract Infection in the 7MM. A detailed picture of the Uromune (MV140) for uncomplicated Urinary Tract Infection in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Uromune (MV140) for uncomplicated Urinary Tract Infection. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Uromune (MV140) market forecast, analysis for uncomplicated Urinary Tract Infection in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in uncomplicated Urinary Tract Infection.

Drug Summary

Uromune is a glycerinated suspension containing whole cell-inactivated bacteria for sublingual administration. It is administered by spraying over the sublingual area. Uromune is intended to be self-administered by the patient. The active substances contained in Uromune are four whole cell-inactivated bacterial strains: Klebsiella pneumoniae (25%), Escherichia coli (25%), Enterococcus faecalis (25%), and Proteus vulgaris (25%) at a final concentration of 300 FTU/mL equivalent to ~109 Bacteria/mL.

MV140 (Uromune) is a polyvalent bacterial preparation (PBP) composed of equal proportions of whole heat-inactivated bacteria producing most RUTI in Europe. MV140 (Uromune) endorses human DCs with the capacity to generate Th1, Th17, and IL-10-producing T cells through mechanisms partially depending on spleen tyrosine kinase (Syk)- and myeloid differentiation primary response gene 88 (MyD88)-mediated signaling pathways. Sublingual immunization of BALB/c mice with MV140 also promotes the generation of systemic Th1, Th17, and IL-10 immune responses in vivo.

Currently, Uromune is pre-licensed in the Phase III development stage, available under the named patient programs (e.g., compassionate use) in 26 countries worldwide (such as the UK, New Zealand, Netherlands, Germany, Spain, and many other Western European countries). Apart from this, the company is also conducting an expanded access program (NCT04173013) for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Uromune (MV140) description, mechanism of action, dosage and administration, research and development activities in uncomplicated Urinary Tract Infection.
• Elaborated details on Uromune (MV140) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Uromune (MV140) research and development activity in uncomplicated Urinary Tract Infection details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Uromune (MV140).
• The report contains forecasted sales of Uromune (MV140) for uncomplicated Urinary Tract Infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for uncomplicated Urinary Tract Infection.
• The report also features the SWOT analysis with analyst views for Uromune (MV140) in uncomplicated Urinary Tract Infection.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Uromune (MV140) Analytical Perspective by DelveInsight

• In-depth Uromune (MV140) Market Assessment

This report provides a detailed market assessment of Uromune (MV140) in uncomplicated Urinary Tract Infection in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• Uromune (MV140) Clinical Assessment

The report provides the clinical trials information of Uromune (MV140) for uncomplicated Urinary Tract Infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for uncomplicated Urinary Tract Infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Uromune (MV140) dominance.
• Other emerging products for uncomplicated Urinary Tract Infection are expected to give tough market competition to Uromune (MV140) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Uromune (MV140) in uncomplicated Urinary Tract Infection.
• Our in-depth analysis of the forecasted sales data of Uromune (MV140) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Uromune (MV140) in uncomplicated Urinary Tract Infection.

 Key Questions

• What is the product type, route of administration and mechanism of action of Uromune (MV140)?
• What is the clinical trial status of the study related to Uromune (MV140) in uncomplicated Urinary Tract Infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Uromune (MV140) development?
• What are the key designations that have been granted to Uromune (MV140) for uncomplicated Urinary Tract Infection?
• What is the forecasted market scenario of Uromune (MV140) for uncomplicated Urinary Tract Infection?
• What are the forecasted sales of Uromune (MV140) in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in uncomplicated Urinary Tract Infection and how are they giving competition to Uromune (MV140) for uncomplicated Urinary Tract Infection?
• Which are the late-stage emerging therapies under development for the treatment of uncomplicated Urinary Tract Infection?